Information Provided By:
Fly News Breaks for January 13, 2017
TSRO
Jan 13, 2017 | 08:05 EDT
Morgan Stanley analyst Andrew Berens initiated TESARO with an Overweight and a $172 price target. The analyst said, based on data from the pivotal NOVA trial in second-line ovarian cancer, niraparib appears to offer a benefit to most ovarian cancer patients that have shown sensitivity to platinum-based chemotherapy and expects that the drug is likely to be granted a broad label by regulatory authorities, which will provides significant commercial advantages.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.